148 related articles for article (PubMed ID: 38033274)
1. Molecular Testing in Non-Small-Cell Lung Cancer: A Call to Action.
Sathiyapalan A; Ellis PM
JCO Oncol Pract; 2024 Jan; 20(1):7-9. PubMed ID: 38033274
[No Abstract] [Full Text] [Related]
2. EGFR mutation testing for squamous cell lung carcinoma.
Liam CK; Leow HR; Pang YK
J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
[No Abstract] [Full Text] [Related]
3. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
4. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
5. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
Planchard D; Remon J; Nowak F; Soria JC
Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
[No Abstract] [Full Text] [Related]
6. Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).
Nellesen D; Dea K; Guerin A; Culver KW; Mutebi A; Dalal A
Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP37-SP42. PubMed ID: 29689141
[No Abstract] [Full Text] [Related]
7. Current concepts on the molecular pathology of non-small cell lung carcinoma.
Fujimoto J; Wistuba II
Semin Diagn Pathol; 2014 Jul; 31(4):306-13. PubMed ID: 25239274
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
Couzin J
Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
[No Abstract] [Full Text] [Related]
9. Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer.
Akerley W
J Natl Compr Canc Netw; 2017 May; 15(5S):689-691. PubMed ID: 28515245
[TBL] [Abstract][Full Text] [Related]
10. Molecular Testing in Lung Cancer: Recommendations and Update.
Borczuk AC
Surg Pathol Clin; 2024 Jun; 17(2):307-320. PubMed ID: 38692813
[TBL] [Abstract][Full Text] [Related]
11. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
12. Molecular testing patterns in metastatic non-small cell lung cancer.
MacLean E; Louder A; Saverno K; Smith G; Mardekian J; Brunis C; Ward M; Sweetman R; Pasquale M
Am J Manag Care; 2016 Feb; 22(2):e60-7. PubMed ID: 26881321
[TBL] [Abstract][Full Text] [Related]
13. [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
Maemondo M
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1314-21. PubMed ID: 25151796
[No Abstract] [Full Text] [Related]
14. Current and future trends in non-small cell lung cancer biomarker testing: The American experience.
VanderLaan PA; Roy-Chowdhuri S
Cancer Cytopathol; 2020 Sep; 128(9):629-636. PubMed ID: 32885913
[TBL] [Abstract][Full Text] [Related]
15. The future of oncology treatment through diagnostic testing.
Oakley G
MLO Med Lab Obs; 2013 Dec; 45(12):38. PubMed ID: 24409595
[No Abstract] [Full Text] [Related]
16. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
17. Comment on "Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-call lung cancer patients" (Cancer Letters 2003;193:207-216).
Gautschi O; Ziegler A
Cancer Lett; 2004 Feb; 204(1):1. PubMed ID: 14744528
[No Abstract] [Full Text] [Related]
18. Molecular Testing of Non-Small Cell Lung Carcinoma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Fine-Needle Aspiration: The Cleveland Clinic Experience.
Doxtader EE; Cheng YW; Zhang Y
Arch Pathol Lab Med; 2019 Jun; 143(6):670-676. PubMed ID: 29372844
[TBL] [Abstract][Full Text] [Related]
19. State of the Art of Pathologic and Molecular Testing.
Dacic S
Hematol Oncol Clin North Am; 2023 Jun; 37(3):463-473. PubMed ID: 36964109
[TBL] [Abstract][Full Text] [Related]
20. Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?
Moffat GT; Wang T; Robinson AG
J Natl Compr Canc Netw; 2023 Feb; 21(4):336-339. PubMed ID: 36791749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
